2025 AAADV WORKSHOP: AGENDA

Robert Califf
Robert Califf

9:00 AM (EST)

Keynote Speaker

Robert Califf (Former Commissioner, US Food and Drug Administration)

Renzo Canetta, MD
Gwen Nichols
...
Richard L. Schilsky

10:00 AM (EST)

What did we learn from trials of different agents from different companies: what's next?

  • Introduction
    10:05am

    Moderator: Renzo Canetta (former Bristol Meyers Squibb- BMS)

  • Beat AML and PedAL
    10:05-10:25 AM

    Speaker: Gwen Nichols (Leukemia and Lymphoma Society- LLS)
    Setting: Hematologic malignancies in adults and children
    Sponsor: The Leukemia and Lymphoma Society (LLS)

  • Lung-MAP
    10:25-10:45 AM

    Speaker: Roy Herbst (Yale)
    Setting: Non-small cell lung cancer
    Sponsor: The Foundation of NIH (FNIH) and Friends of Cancer Research (FOCR)

  • NCI-MATCH
    10:45-11:05 AM

    Speaker: James Ford (Stanford)
    Setting: Solid tumors and lymphomas
    Sponsor: National Cancer Institute (NCI)

  • TAPUR
    11:05-11:25 AM

    Speaker: Rich Schilsky (University of Chicago)
    Setting: Solid tumors, myeloma, B-cell lymphomas
    Sponsor: American Society of Cancer Research (ASCO)

  • Critical Panel Review and Discussion
    11:25AM-12:00PM

    Title: From signal identification to future standard of care combinations: a suitable regulatory pathway?
    Moderator: Gideon Blumenthal (Merck)

12:00 –12:30 PM (EST)

Lunch Break

Jaap Verweij
Jaap Verweij
Jennifer Dent
Denis Lacombe
Denis Lacombe
...

Panel Discussion:
A Perspective on International/Global Clinical Trials in Oncology

5:00 PM (EST)

End

Richard L. Schilsky

9:00 AM (EST)

Developing and Implementing Complex Biomarkers to Guide Cancer Treatment

Moderator:  Richard Schilsky (University of Chicago)

...
Olivier Elemento
Olivier Elemento
...

...

  • Role of AI in Cancer Drug and Biomarker Development
    9:05 AM

    Olivier Elemento, (Weill Cornell)

  • Network analysis to identify novel biomarkers/targets
    9:30 AM

    Andrea Califano (Columbia University)

  • Clinical application of transcriptomics in precision oncology
    9:50 AM

    Funda Meric-Bernstam (MD Anderson)

  • Digital pathology to identify actionable molecular targets
    10:10 AM

    Eric Walk (Path.AI)

  • AI-informed digital pathology to predict homologous recombination deficiency
    10:30 AM

    Ludmil Alexandrov (University of California, San Diego- UCSD)

  • Discussion
    11:30 AM

    Discussion Moderator: Richard Schilsky (University of Chicago)

12:00 PM – 1:00 PM (EST)

Lunch Break

Thomas Fleming, PhD​
Thomas Fleming, PhD​
...
...

Choosing Proper Primary Endpoints in Registrational Oncology Trials, with Focus on the Indolent Cancer Setting

Moderator: Tom Fleming (Univ of Washington)

  • Reliable assessment of efficacy and safety in oncology trials, with focus on indolent cancers
    1:05 PM

    Thomas Fleming (Univ of Washington)

  • The Importance of evaluating effects on how patients feel and function: A Patient Perspective
    1:30 PM

    Loriana Hernandez (Patient Advocate)

  • The development and proper qualification of Patient Reported Outcome
    2:00 PM

    John Powers (George Washington University School of Medicine)

  • Discussion- Regulatory Perspective Suggested
    2:30 PM

    Discussion Moderator: Tom Fleming (Univ of Washington)

3:00 PM (EST)

End